[Treatment of hypogonadism in girls after treatment for cancer].
Pienkowski
C
C
Unité d'Endocrinologie, Génétique, Pathologie Osseuse et Gynécologie Médicale, Hôpital des Enfants, Hôpital Paule-de-Viguier, Toulouse, France. pienkowski.c@chu-toulouse.fr
Cartault
A
A
Lamiche-Lorenzini
F
F
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000009:adverse effects / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007006:Hypogonadism / Q000139:chemically induced* / Q000523:psychology / Q000628:therapy*; D007247:Infertility, Female / Q000139:chemically induced / Q000523:psychology; D009369:Neoplasms / Q000188:drug therapy* / Q000523:psychology; D010348:Patient Care Team; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000523:psychology; D011374:Progesterone / Q000009:adverse effects / Q000627:therapeutic use; D011627:Puberty / Q000187:drug effects; D012727:Sex Characteristics
D000970:Antineoplastic Agents; D011374:Progesterone; D004958:Estradiol